BridgeBio Q2 2022 revenue $73.7M, net loss $9.9M; cash $688.6M; pipeline data positive

BridgeBio Pharma, Inc.

2022-Q2 EPS reported -$1.41 revenue$75,440,000

Net loss attributable to common stockholders of $9.9M ($0.07 per share) vs $96.3M loss a year ago; revenue $73.7M from NULIBRY and licensing.
Cash and equivalents $688.6M, providing runway into 2024; two-year deferral on senior debt principal repayment to Nov 2026.
Positive Phase 2 interim data for infigratinib in achondroplasia: mean AHV increase 1.52 cm/year; added Cohort 5.
Entered exclusive license with BMS for BBP-398 (SHP2 inhibitor) for up to $905M; received $90M upfront; sold PRV for $110M.
Selected next-gen KRAS G12C dual inhibitor candidate; plans to begin clinical work mid-2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.